May 26, 2025
What Is MASH? Understanding Fatty Liver Disease and Why It's More Common Than You Think
Most people have never heard of MASH. Yet it affects an estimated 6–8% of the global population and is rapidly becoming one of the leading causes of liver transplants in the United States. It progresses silently, often with no symptoms until significant damage has already occurred — which is exactly why understanding it matters, and why early detection can change the outcome entirely.
What Is MASH and How Is It Different From Fatty Liver?
MASH stands for Metabolic dysfunction-Associated Steatohepatitis. It is an advanced form of fatty liver disease — a condition in which excess fat accumulates in the liver cells and begins to cause inflammation and damage.
Fatty liver disease exists on a spectrum. The earliest stage, MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease), involves fat buildup without significant inflammation. When that fat accumulation triggers active liver inflammation and cell injury, the condition becomes MASH. Left unaddressed, MASH can progress to fibrosis — scarring of the liver tissue — and eventually to cirrhosis, liver failure, or liver cancer.
Who Is at Risk?
MASH does not discriminate, but certain factors significantly increase your risk. You may be at elevated risk if you have any of the following:
Type 2 diabetes or insulin resistance
Obesity, particularly excess abdominal fat
High cholesterol or elevated triglycerides
Hypertension
Metabolic syndrome
A sedentary lifestyle combined with a high-calorie diet
Hispanic populations — who make up a significant portion of Miami's community — face a disproportionately higher risk of MASLD and MASH compared to other ethnic groups, due to a combination of genetic and metabolic factors. This makes access to screening and research participation especially important in Miami.
Why Most People Don't Know They Have It
The most dangerous characteristic of fatty liver disease is that it produces no obvious symptoms in its early and middle stages. No pain. No fatigue that stands out. No visible signs. Most people feel completely normal while the condition silently advances over years or even decades.
By the time symptoms do appear — abdominal discomfort, fatigue, yellowing of the skin — the disease has often already reached an advanced stage. This is why routine screening, particularly for people with known risk factors, is so critical.
Is There a Treatment for MASH?
Until recently, there were no FDA-approved treatments specifically for MASH. That is beginning to change. The first MASH-specific drug received FDA approval in 2024, and multiple additional treatments are currently in Phase II and Phase III clinical trials — several of which are being conducted right here in Miami at Evolution Clinical Trials.
Participating in a MASH study gives qualifying patients access to treatments that are not yet available to the general public, combined with free medical monitoring, free lab work including FibroScan imaging, and compensation for their time.
How Evolution Clinical Trials Is Helping Miami Patients
Evolution Clinical Trials is currently enrolling participants in Miami for MASH and fatty liver disease studies in partnership with leading pharmaceutical sponsors. Qualifying patients receive a free FibroScan — a non-invasive liver scan that detects fat and scarring in minutes — as part of the screening process.
Whether or not you qualify for a study, the scan and results are yours at no cost. For many Miami patients, it is the first clear picture they have ever received of their liver health.
Find Out Where You Stand — For Free
If you have risk factors for fatty liver disease and have never been formally screened, this is the most straightforward step you can take. A free FibroScan at our Miami clinic takes under 10 minutes, requires no preparation, and gives you real answers.
Schedule your free scan today at evolutionclinicaltrials.com or call our Miami clinic to book your appointment.
